I attended this years Stockholm Corporate Finance Life Science Seminar which is run every year and this is my 3rd year of attending.
More than 400 people participated in the Stockholm Corporate Finance Ninth Life Science seminar held on 21 and 22 March in cooperation with us at Financial Hearings and the news agency Direct. There were 16 companies that presented. These corresponding to a total market value of approximately SEK 15 billion. Investor Interest in Life Science sector continues to increase among both institutions, asset managers and private equity investors.
SCFs CEO Peter Enstrom began by informing about the present, 16 companies are an important part of the Swedish Life Science industry. Many companies are relatively small and are working under difficult financial circumstances, but their research, which in recent years has become increasingly sophisticated, will change many people’s health and lives. “Research with the support of venture capital is a necessity today to get a broad and vigorous Swedish Life Science industry to compete in the international market with the goal of becoming a world leader.”
Addlife, Bactiguard, Camurus, Dignitana US Inc, Hansa Medical, index Pharma, IRLAB, Karolinska Development, MedCap, Medivir Pharma Moberg, Oasmia Pharmaceutical, Orexo, Redwood Pharma SciBase, and Wnt Reserarch.